Crimson Publishers Publish With Us Reprints e-Books Video articles


Global Journal of Endocrinological Metabolism

The Vasopressin V2 Receptor Antagonists: The Vaptans

  • Open or Close Michael AB Naafs*

    Naafs International Health Consultancy, Europe

    *Corresponding author: Michael AB Naafs, Internist-endocrinologist with a long clinical career in internal medicine and endocrinology, Naafs International Health Consultancy, Europe

Submission: March 26, 2018; Published: April 24, 2018

DOI: 10.31031/GJEM.2018.02.000529

ISSN 2637-8019
Volume2 Issue1


In this mini-review the pathogenesis and pathophysiology of the new vasopressin antagonists are discussed. Indications, appropriate and inappropriate use of the vaptans are evaluated. The efficacy and safety of the vaptans has been well established. Costs are high and the vaptans are not cost-effective in the long-term treatment of autosomal dominant polycystic kidney disease (APDKD) with a cost of U.S. $744.100 per equally adjusted life year (QALY) gained compared to standard care. This is seven times the standard willingness to pay tres hold. A secondary analysis of the SALT trials reached no significant beneficial cost-benefit analysis for to vaptan in the treatment of patients with the syndrome of in appropriate secretion of antiduretc hormone (SIADH). U.S. and European expert panels released different treatment guidelines. Solid endpoint studies on the increased mortality of hyponatremia are lacking.

Get access to the full text of this article

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137